Advancing Care with Selective IL-23 Inhibition

Pyoderma gangrenosum (PG) presents a significant therapeutic challenge for clinicians worldwide. Conventional therapies often lead to incomplete responses or severe cumulative toxicity. However, selective IL-23 inhibition has emerged as a promising strategy for patients who do not respond to standard care. A recent multicenter retrospective study explored the effectiveness of this approach in refractory cases.

The study followed adult patients treated with inhibitors like guselkumab, risankizumab, or tildrakizumab. Researchers noted a progressive reduction in total ulcer area among the participants. This improvement was statistically significant as early as one month into the treatment. Furthermore, the number of active ulcers decreased notably from the third month onwards.

Clinical Benefits of Selective IL-23 Inhibition

Beyond physical healing, patients experienced a substantial decrease in pain intensity. The Numerical Rating Scale (NRS) scores dropped consistently throughout the observation period. Additionally, the therapy showed a remarkable steroid-sparing potential. This feature is crucial because long-term corticosteroid use often causes debilitating side effects. Consequently, these findings suggest that targeting the IL-23/IL-17 axis could redefine PG management paradigms.

Safety remained a priority during the investigation. The researchers observed that the inhibitors were generally well-tolerated by the patient cohort. Therefore, selective IL-23 inhibition offers a safer alternative to traditional immunosuppressants like cyclosporine. Patients with comorbid conditions may particularly benefit from this targeted mechanism of action.

Improving Patient Outcomes in Refractory PG

Managing refractory PG requires a shift toward personalized medicine. This study provides strong evidence that IL-23 blockade is both effective and rational. Since the response starts early, clinicians can better manage patient expectations and treatment goals. Overall, this therapeutic shift represents a major step forward in dermatological care.

Frequently Asked Questions

What are selective IL-23 inhibitors?

These are monoclonal antibodies that specifically target the p19 subunit of interleukin-23. Common examples include guselkumab, risankizumab, and tildrakizumab, which are increasingly used for refractory inflammatory skin conditions.

Why is selective IL-23 inhibition useful in pyoderma gangrenosum?

The IL-23/IL-17 axis plays a central role in the pathogenesis of pyoderma gangrenosum. By blocking this specific pathway, these drugs reduce neutrophilic infiltration and promote faster wound healing in chronic ulcers.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or substitute for professional consultations. Refer to the latest local and national guidelines for clinical practice.

References

1. Bettolini L et al. Selective IL-23 Inhibition in Conventional Treatment-Refractory Pyoderma Gangrenosum: A Multicenter, Retrospective Study. Int J Dermatol. 2026 Apr 18. doi: 10.1111/ijd.70430. PMID: 42001205.


2. Croitoru DO et al. The Clinical and Molecular Response of Pyoderma Gangrenosum to IL-23 Blockade: Result from a Proof-of-Concept Open-Label Clinical Trial. J Invest Dermatol. 2025 Jun;145(6):1396-1406.


3. Reese AM et al. Guselkumab as a treatment option for recalcitrant pyoderma gangrenosum. JAAD Case Rep. 2020;8:43-46.